Skip to main navigation Skip to search Skip to main content

HMG CoA reductase inhibitors (statins) for dialysis patients

  • Sankar D. Navaneethan
  • , Sagar U Nigwekar
  • , Vlado Perkovic
  • , David W. Johnson
  • , Jonathan C. Craig
  • , Giovanni F.M. Strippoli

Research output: Contribution to journalReview articlepeer-review

83 Citations (Scopus)

Abstract

Dialysis patients are at high risk of heart disease. Statins have been shown to decrease cholesterol levels and mortality in the general population. We aimed to determine if a similar effect has been established in dialysis patients. This review identified 14 studies ‐ 13 comparing statins with placebo and one comparing statins to another lipid lowering agent. Statins decreased cholesterol levels to a level similar to that seen in the general population and were safe. One large study did not find any major mortality benefits with statins even though it reduced the number of cardiovascular events in dialysis patients.
Original languageEnglish
Article numberCD004289
JournalCochrane Database of Systematic Reviews
Issue number3
Publication statusPublished - 8 Jul 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • dialysis
  • kidney disease
  • cardiovascular disease
  • Statins

Fingerprint

Dive into the research topics of 'HMG CoA reductase inhibitors (statins) for dialysis patients'. Together they form a unique fingerprint.

Cite this